Introduction
Prostate cancer (PCa) is the most common malignant tumor in men and carries significant morbidity and mortality [1] . Substantial improvements have been made in the molecular characterization of this disease, but these have not yet been translated into relevant stratification in clinical practice [2] .
Loss of the tumor suppressor phosphate and tensin homolog (PTEN) is one of the most common molecular aberrations in PCa and has been correlated with a poor prognosis [3] [4] [5] [6] [7] [8] [9] [10] . As a lipid phosphatase and negative regulator of the PI3K/AKT/mTOR pathway, PTEN controls a number of cellular processes including survival, proliferation, metabolism, migration, and cellular architecture [11] . Preclinical data have proposed a role for PTEN loss and activation of the PI3K/AKT pathway in regulating androgen receptor (AR) transcriptional output and in driving resistance [5, [12] [13] [14] .
PTEN has attracted great interest as a biomarker in PCa. Initial assessments of PTEN loss mostly focused on genomic deletions of the PTEN locus identified by fluorescence in situ hybridization (FISH) [7, 15] . However, multiple mechanisms account for loss of PTEN protein expression including genomic deletion, mutation, microRNA, and promoter methylation [16] , and FISH may therefore be systematically underestimating the frequency of loss of PTEN in PCa [8, [15] [16] [17] [18] .
Reliable analysis of PTEN status by immunohistochemistry (IHC) in routinely processed clinical formalin-fixed and paraffin-embedded (FFPE) pathology specimens has been established [19] , and good concordance has been demonstrated between FISH detection of PTEN deletions and the overall cellular PTEN protein expression by IHC [8, 15, 18, 20] . Importantly, assessment of PTEN protein expression by IHC offers the advantage of detecting loss of PTEN by mechanisms other than genomic deletion [8, 15] .
In this retrospective study we investigated PTEN protein expression in hormone-naive prostate cancer and castration-resistant prostate cancer (CRPC) tissue and its association with clinical outcome in metastatic CRPC patients treated with the CYP17 inhibitor abiraterone acetate (abiraterone).
2.
Patients and methods
Patient cohort
Potentially eligible cases were identified from a population of men with 
PTEN immunohistochemistry
PTEN protein expression was determined by IHC on 4-mM-thick FFPE sections as previously described [15, 21] . Briefly, PTEN immunoreactivity was investigated using a rabbit monoclonal anti-PTEN antibody 138G6
(catalog no. 9559; Cell Signaling Technology, Inc, Danvers, MA, USA) [19] detected using the Vectastain Elite ABC kit (catalog no. PK-6101; Vector
Laboratories, Burlingame, CA, USA). Nuclear and cytoplasmic staining intensity were semiquantitatively assessed using the H-score formula: 
Fluorescence in situ hybridization
PTEN FISH was performed as described previously [7, 21, 23] 
Statistical analyses
Biochemical response to abiraterone was defined per the Prostate Cancer
Working Group Criteria 2 as a 50% decline in prostate-specific antigen
(PSA) from baseline, confirmed at least 3 wk later [24] . Survival was measured from the first date of abiraterone treatment to the date of last contact or to the date of death from any cause. The Kaplan-Meier productlimit method was used to estimate the duration of abiraterone treatment and overall survival. Independent sample t tests and Pearson chi-square were used to study the association of PTEN loss with continuous and categorical variables, respectively. All tests were two sided, and a p value 0.05 was considered statistically significant. Univariate and multivariate analyses of the independent factors for overall survival were performed using the Cox regression model with a 95% confidence interval (CI). High/ low values for accepted normal ranges were used for laboratory parameters [25] . PSA was highly skewed, and the logarithm function was used to transform this variable. Twenty-seven patients had at least one missing baseline variable. Descriptive statistics and survival analyses were performed using IBM SPSS Statistics v.22.
Results

Validation of immunohistochemical cut-off
Because no validated standard definition for PTEN positivity or loss by IHC exists, we first determined if our PTEN IHC assay and binary classification system was sensitive for detecting PTEN loss in clinical PCa specimens. We evaluated PTEN protein by IHC in a series of PCa specimens for which we had available PTEN genomic status by FISH (n = 103). In patients with no deletion of PTEN, a variable degree of cytoplasmic and nuclear PTEN protein immunostaining was evident ( Fig. 1 ), whereas patients with homozygous loss of both PTEN alleles had loss of PTEN protein by IHC with a median cytoplasmic H-score of 0 (range: 0-10) (Fig. 1 ). According to our classification system, 100% of patients with homozygous loss were classified as PTEN negative. PTEN expression in patients with heterozygous loss was low/absent with a median cytoplasmic PTEN H-score of 0 (range: 0-80) ( Fig. 1 ), confirming previous observations that patients with heterozygous loss commonly have loss of PTEN expression by IHC [8, 15] . Taken together, these results confirmed our PTEN IHC was sensitive for the detection of genomic PTEN loss and the validity of our cut-off to classify PTEN status. Two inserted photographs at T200 magnification demonstrate cytoplasmic positivity (upper right: short dashes square) and negativity (bottom left: long dashes square). Nuclear staining was predominantly negative in both areas.
(B) Column B shows three matched metastatic castration-resistant prostate cancer samples acquired at a later time point from the same patients as the respective diagnostic samples in column A. (B1, B2) PTEN negativity has been verified in bone marrow and liver metastases, respectively (T200 magnification). (B3) PTEN nuclear and cytoplasmic positivity is demonstrated in tumor nests of a lymph node biopsy (T200 magnification). CRPC = castration-resistant prostate cancer. [ high lactate dehydrogenase levels, and the presence of visceral metastases were identified as independent factors for overall survival in multivariate Cox regression analysis ( Table 2) . Confirmed PSA declines of at least 50% in the absence of radiographic progression were observed in 18 of the 56 patients with loss of PTEN (32%) and in 38 of the 87 patients (43%) ( p = 0.2). The median duration of abiraterone treatment for patients in the PTEN-negative group was shorter than that for the PTEN-positive group (24 vs 28 wk; HR: 1.6; 95% CI, 1.12-2.28; p = 0.009) ( Table 3 ).
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Discussion
Loss of PTEN is a common molecular aberration in PCa and believed to be critically important in regulating AR signaling output [5, 13, 14] . Preclinical studies have demonstrated the existence of reciprocal feedback regulation between the AR and PI3K/AKT pathway in PTEN-deficient models that confers survival advantage and resistance to single pathway inhibition [5, 26] . In this retrospective study we investigated PTEN expression in metastatic CRPC patients who had received treatment with abiraterone post-docetaxel and its association with clinical outcome. We used a specific antibody directed against the extreme carboxy-terminal sequence of human PTEN protein [3, 8, 15, 19] and used a stringent cut-off to define PTEN negativity that was validated in cases with biallelic genomic losses by FISH. Loss of PTEN expression occurred in 40% of patients and was associated with a shorter duration of abiraterone treatment and poorer overall survival. The study was retrospective in design with the inherent biases and confounders of all retrospective studies including the lack of data on comorbidities and comprehensive data on tumor volume and radiologic responses. Nonetheless, our data indicate that patients with loss of PTEN may have a worse clinical outcome when treated with abiraterone. These findings require replication in an independent data set but support the evaluation of PTEN as a biomarker in trials with combinations of novel AR-targeting drugs (abiraterone or enzalutamide) and PI3K/AKT inhibitors for patients with CRPC.
Inherent in PCa studies is intratumoral heterogeneity that can lead to misclassification and confound the association with outcomes. In keeping with previous studies, heterogeneity of PTEN expression was observed in 6% of primary tumors, mostly obtained in our cohort by needle biopsies [3, 8] . Nevertheless, with our binary classification system, we observed good concordance (90%) between same-patient samples collected at multiple time points and in matched HSPC and CRPC tissue (86%). These findings require further validation in large independent cohorts, with possible interrogation of heterogeneity in primary and especially in metastatic disease.
Conclusions
To the best of our knowledge, this is the first report of an association between PTEN protein expression status and clinical outcome in metastatic CRPC patients. PTEN loss has been shown to be frequently, but not always, associated with the presence of transmembrane protease, serine 2-vets avian erythroblastosis virus E26 oncogene homolog (TMPRSS2-ERG) rearrangements [9, 27, 28] . Discordant results have been published concerning the prognostic effect of loss of PTEN in the contest of ERG fusion [7, 9, 29, 30] . PTEN loss is also accompanied by frequent alterations in the PI3K/AKT signaling pathway network involving inositol polyphophate-4 phosphatase, type II, 105kDa (INPP4B); PH domain and leucine rich repeat protein phosphatase 1 (PHLPP); and phosphoinositide-3-kinase, regulatory subunit 1 (alpha) (PIK3R1) [27] . Characterization of PTEN, along with ERG and possibly other key proteins implicated in this pathway, as part of larger studies with well-powered analyses are now warranted to better define the impact of PTEN loss on response to novel AR-targeting agents including studies of their interaction with ETS gene rearrangements.
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